PARPi significantly inhibited the proliferation of NKTCL cells in a dose-dependent manner (Fig. 1A), and NKTCL cells were more sensitive to niraparib (IC50 values for NKYS, KHYG1, YT, SNK6, and NKL were respectively 1.45 μM, 3.43 μM, 7.15 μM, 3.00 μM, and 11.64 μM) and fluzoparib (IC50 values for NKYS, KHYG1, YT, SNK6, and NKL were respectively 0.88 μM, 2.22 μM, 5.68 μM, 3.40 μM, and 17.59 μM). Here, GLIS2 is linked to extranodal nasal NK/T cell lymphoma.